Gilenya is a sphingosine 1-phosphate receptor modulator. The exact mechanism is unknown, but Gilenya is thought to work by reducing the immune system‘s attack on the central nervous system by retaining certain white blood cells (lymphocytes) in the lymph nodes.
Gilenya is specifically indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Gilenya is supplied as a capsule designed for oral administration. The recommended initial dose is 0.5 mg orally once daily, with or without food.